Rein Therapeutics awarded to patents related to LTI-03

Rein Therapeutics (RNTX) announced that the U.S. Patent and Trademark Office, or USPTO, granted two new patents related to Rein’s lead product candidate, LTI-03, a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling, which is administered through dry powder inhalation. U.S. Patent No. 12,280,088 and U.S. Patent No. 12,280,089, both titled, “Dry Powder Formulation of Caveolin-1 Peptides and Methods of Use Thereof”, were issued on April 22, 2025. The patents cover LTI-03 dry powder inhalation formulation and its therapeutic use for treating various lung diseases including interstitial lung disease, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), asthma and other inflammatory or fibrotic lung conditions.